Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.54 USD | -2.53% | -0.65% | +35.09% |
May. 30 | NextCure, Inc. Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024 | CI |
May. 02 | NextCure, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 43.08M |
---|---|---|---|---|---|
Net income 2024 * | -49M | Net income 2025 * | -50M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.88
x | P/E ratio 2025 * |
-0.91
x | Employees | 82 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.11% |
1 day | -2.53% | ||
1 week | -0.65% | ||
1 month | +12.41% | ||
3 months | -13.97% | ||
6 months | +28.33% | ||
Current year | +35.09% |
Managers | Title | Age | Since |
---|---|---|---|
Michael Richman
FOU | Founder | 63 | 15-11-30 |
Steven Cobourn
DFI | Director of Finance/CFO | 61 | 17-12-31 |
Han Myint
CTO | Chief Tech/Sci/R&D Officer | 71 | 21-01-13 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Kabakoff
CHM | Chairman | 76 | 15-11-30 |
Michael Richman
FOU | Founder | 63 | 15-11-30 |
Chau Khuong
BRD | Director/Board Member | 48 | 15-11-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 1.54 | -2.53% | 70,350 |
24-05-30 | 1.58 | -1.86% | 54,306 |
24-05-29 | 1.61 | +6.62% | 498,706 |
24-05-28 | 1.51 | -2.58% | 19,788 |
24-05-24 | 1.55 | -3.73% | 67,017 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+35.09% | 43.08M | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B | |
+77.64% | 8.87B |
- Stock Market
- Equities
- NXTC Stock